A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a ...

Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

Breast cancers driven by a particular genetic signature can already be treated by a particular class of targeted therapies, but the race is on to develop next-generation medicines that improve the ...

A new study helps explain why a promising class of cancer drugs has often failed to meet expectations in clinical trials.

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...

Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases.

SAN FRANCISCO (KGO) -- Bay Area researchers are fighting back against a particularly deadly form of cancer and they're doing it with a new generation of drugs. These drugs enlist the body's own immune ...

Adcendo secures $75M Series C funding to advance innovative cancer therapies and expand its antibody-drug conjugate pipeline.

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect. The compound was developed by Lawrence Livermore National ...

Researchers at the University of Colorado Anschutz have discovered that certain cancer drugs impact a specific protein that regulates taste buds. The findings, published in Development, could lead to ...

In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...